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Introduction
The guidelines project is a joint initiative of the Associação Médica Brasileira and 
the Conselho Federal de Medicina. It aims to bring together information in medicine to 
standardize conduct in order to help decision-making during treatment. The data contained 
in this manuscript were prepared by and are recommended by the Associação Brasileira 
de Hematologia, Hemoterapia e Terapia Celular. Even so, all possible conducts should be 
evaluated by the physician responsible for treatment depending on the patient’s setting and 
clinical status.
Description of the method used to gather evidence:
These guidelines were drafted after constructing 19 questions relevant to the diagnosis 
and treatment of Chronic myeloid leukemia (CML). The questions were structured using 
the PICO (patient-intervention-comparison-outcome) methodology, thus enabling the 
creation of strategies to search for evidence (Appendix 1) in the main scientific electronic 
databases (Medline/PubMed, Embase, Lilacs/SciELO, Cochrane Library, PreMEDLINE 
via OVID). Moreover a manual search for evidence in dissertations and theses was carried 
out (Biblioteca Digital de Teses e Dissertações do Instituto Brasileiro de Informação em 
Ciência e Tecnologia – BDTD/IBICT). Evidence was selected by critical evaluation using 
discriminatory instruments (scores) according to the category of question: diagnosis (Quality 
in Diagnostic and Screening tests - QADAS) or therapy (JADAD for randomized clinical 
trials and Newcastle-Ottawa scale for non-randomized studies). After identifying potential 
studies to substantiate recommendations, the level of evidence and degree of recommendation 
were calculated using the classification of Oxford (available at www.cebm.net).
Summary of the degree of recommendation and level of evidence:
A: Major experimental and observational studies.
B: Minor experimental and observational studies.
C: Case reports (non-controlled studies).
D: Opinion without critical evaluation based on consensus, physiological studies or 
animal models.
Aims
To set parameters for clinical diagnosis, evaluate severity and standardize treatment, 
maintenance and monitoring options for CML patients. The target audience of these guidelines 
is the hematologist with the aim of contributing to decision making in the diagnosis and 
treatment of CML.
What are the diagnostic criteria for Chronic myeloid leukemia?
The diagnosis of CML is based on leukocytosis and often also thrombocytosis, and 
on the differential blood count (immature granulocytes, metamyelocytes, myeloblasts and 
basophilia). Diagnosis depends on the identification of the Philadelphia chromosome (22q) 
resulting from the t(9;22)(q34;q11) resulting in the head to tail fusion of Breakpoint Cluster 
Region (BCR) and the Abelson Murine Leukemia (AML) genes or identification of the result 
of this translocation in peripheral blood or bone marrow cells. In some cases, the Philadelphia 
chromosome cannot be detected and diagnosis is made by molecular methods. The typical 
clinical course has three stages: the chronic phase, the accelerated phase and the blast crisis 
phase. Most diagnoses are made in the chronic phase. The accelerated phase is defined as 
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the presence of 1% to 19% blasts in the blood or bone marrow, 
basophils > 20%, thrombocytosis or thrombocytopenia not related 
to therapy and clonal evolution in cytogenetic evaluation. The 
blast crisis phase is characterized by blasts > 20% of peripheral 
blood white cells or extramedullary blast proliferation(1-3)(D).
Recommendation: Diagnosis of CML depends on the 
identification of the Philadelphia chromosome or the 
BCR-ABL rearrangement.
Is there any difference in the prognosis of CML patients 
with p210 e13a2(b2a2) and e14a2(b3a2) or (e1a2)
p190 rearrangements?
The prevalence of the e1a2 BCR-ABL fusion transcript 
in CML patients is 1%. This rearrangement is associated with 
decreased therapeutic response to tyrosine kinase inhibitors 
(TKIs) as complete hematologic response is attained in only 30% 
of cases, complete cytogenetic response in 20% (3 to 18 months) 
and major molecular response in 10% of cases. Progression to 
other phases (accelerated or blast crisis) occurs in 60% of chronic 
phase patients(4)(C).
The response of treatment-naïve CML patients to imatinib 
treatment is different for the b3a2(e14a2) and b2a2(e13a2) 
transcripts. In 12 months of treatment, patients with the 
b3a2(e14a2) transcript have a 29% increase in complete 
cytogenetic response, which is faster, and greater disease-free 
survival(5)(B).
In CML patients on imatinib treatment for six months, the 
number of b2a2(e13a2) transcripts is lower when compared to the 
number of b3a2(e14a2) transcripts, suggesting greater sensitivity 
of the b2a2(e13a2) transcripts to imatinib and consequently 
prognosis is better(6)(B).
Imatinib treatment in chronic-phase CML patients with the 
BCR-ABL b2a2(e13a2) transcript has better results compared to 
those with the b3a2(e14a2) transcript with a 31% increase in the 
major cytogenetic response and a smaller number of BCR-ABL 
transcripts(7)(B).
Recommendation: the (e1a2)p190 transcript is associated 
to a reduced therapeutic response; there is controversy as 
to whether there is difference in response between the 
p210 e13a2(b2a2) and p210 e14a2(b3a2) transcripts.
At diagnosis, do the Philadelphia chromosome and 9q 
deletion have prognostic significance?
There is no difference in survival between CML patients 
with the chromosome 9q deletion on interferon alpha treatment 
and those without this deletion. However, there is a reduction in 
the survival of patients with the deletion spanning the BCR-ABL 
junction compared to those without this deletion. The survival 
rate is 44% higher in chronic phase patients submitted to bone 
marrow transplantation who do not have the deletion (Number 
needed to treat - NNT: 2)(8)(B). There is evidence that the 
disease-free survival, overall survival and cytogenetic response 
is reduced in CML patients with the chromosome 9q34 deletion 
under treatment with interferon alpha(9,10)(B).
A comparison of first-generation (imatinib) or second-
generation (nilotinib or dasatinib) TKIs in the treatment of CML 
patients with chromosome 9 deletion shows that there is no 
significant difference in the overall survival, disease-free survival 
or in cytogenetic response between patients with and without 
the chromosome 9 deletion over a two-year follow-up(11,12)(B). 
There is, however, evidence that there is a reduction in survival 
of patients with derivative chromosome 9 deletions(13)(B).
The ABL deletion on derivative 9 (15.1%) in CML patients 
reduces disease-free survival, the BCR deletion reduces overall 
survival and combined ABL and BCR deletions reduce the 
overall and disease-free survival(14,15)(B). There is evidence that 
only the ABL deletion reduces the survival time and the duration 
of the chronic phase(16)(B).
Over a 5-year follow up of imatinib treatment, CML patients 
with variant Philadelphia chromosome translocations do not 
demonstrate significant differences in overall survival, disease-free 
survival, progression-free survival, complete hematological response, 
cytogenetic response or molecular response compared to patients 
without variant Philadelphia chromosome translocations(17,18)(B). 
Other studies have shown that Philadelphia chromosome mosaicism 
increases mortality in 3.3 years by 21% (NNH: 5) and translocation 
variations reduce cytogenetic response(19,20)(B).
Recommendation: Despite controversy on whether 
chromosome 9q, BCR deletions and variant Philadelphia 
chromosome translocations confer worse prognoses, 
there is evidence of reductions in overall and disease-
free survival and in therapeutic response of CML 
patients treated with interferon alpha or first-generation 
and second-generation TKIs. ABL deletion reduces the 
overall and disease-free survival of patients. The presence 
of variant Philadelphia chromosome translocations and 
mosaicism also seem to confer worse prognosis in CML.
Do cytogenetic abnormalities in addition to the 
Philadelphia chromosome at diagnosis have prognostic 
significance?
In CML patients under treatment using first-generation 
(imatinib) and second-generation (dasatinib or nilotinib) TKIs, 
the presence of additional chromosomal abnormalities reduces 
disease-free and overall survival at 5 years(21)(B).
The presence of additional chromosomal aberrations in 
CML patients under treatment with nilotinib increases mortality 
by 28% due to disease progression (NNH: 4). In addition, 
mortality is increased by 38% at 2 years in chronic phase patients 
with additional chromosomal aberrations (NNH: 3)(22)(B).
Aberrations reduce the survival time of these patients(23,24)(B). 
The presence of additional chromosomal aberrations increases 
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Is it important to define risk in CML patients using the 
Sokal and Hasford scores?
The Sokal score can be determined using an online calculator 
(www.pharmacoepi.de). The score takes into account the size of 
the spleen (in centimeters) palpable below the left costal border, 
the platelet count, the percentage of blasts and the age, where a 
result < 0.8 corresponds to low risk, from 0.8 to 1.2 intermediate 
risk and > 1.2 high risk. The Sokal score has a predictive value 
in CML patients treated with imatinib, where molecular and 
cytogenetic responses are higher in low-risk patients. High-risk, 
intermediate-risk and low-risk patients who achieve cytogenetic 
response within 12 months have probabilities of survival of 90%, 
94% and 97%, respectively. 
The Hasford score considers the age, the percentage 
of eosinophils and basophils, platelet count, spleen size in 
centimeters and percentage of blasts; the patient has low 
risk when the result is ≤ 780, intermediate risk between 780 
and 1480 and high risk ≥ 1480. The 5-year survival rate 
corresponding to each risk group is 76%, 55% and 25%, 
respectively(31)(D)(32)(B).
The Sokal score predicts treatment response of 
CML patients on interferon alpha therapy. The high-risk, 
intermediate-risk and low-risk groups include 48%, 29% and 
23% of the cases with mean survival rates of 45, 76 and 105 
months, respectively. The 10-year survival is 8%, 28% and 
34%, respectively(33)(B).
After the introduction of imatinib treatment, the Sokal score 
identified an increase in the 5-year survival rate of low-risk CML 
patients of 11%, intermediate-risk patients of 40% and of high-
risk patients of 38%(34)(B). Moreover, it is known that high-risk 
patients are more likely to evolve to the accelerated or blast crisis 
phases even on imatinib therapy(35)(A). The Sokal score is also 
inversely related to cytogenetic response in high-risk patients(36)
(B), as, for high-risk patients, there is a 30.4% reduction in 
cytogenetic response(37)(B).
The Hasford score identifies patients at low risk, with 
probability of survival at 9 years of 41%, intermediate risk, with 
probability of 0.16%, and high-risk, with a probability zero at 
9 years. The Sokal and Hasford scores classify 23% and 9% 
of all patients as high-risk, respectively. Patients with low or 
intermediate risk who achieve complete hematological response, 
have probabilities of survival of 51% and 23%, respectively; 
those without complete hematologic response have probabilities 
of 26% and 12%, respectively. High-risk patients who achieve 
cytogenetic response have prognoses similar to those with low 
risk(38)(B). Of the different groups as classified by Hasford, 57% 
of low-risk patients present complete cytogenetic response and 
27% of intermediate-risk and high-risk patients achieve complete 
cytogenetic responses(39)(B).
The Hasford and Sokal scores predict complete 
hematological responses mainly in low-risk patients(40)(B).
Recommendation: The Sokal and Hasford scores are 
prognostic predictors of CML patients.
mortality by 36% (NNH: 3) and reduces the mean overall survival 
of CML patients submitted to stem cell transplantation(25)(B).
CML-related disease-free and overall survival at 5 years 
is different in patients with cytogenetic changes compared to 
those without. The presence of major cytogenetic aberrations 
(major route abnormalities) (such as a second Philadelphia 
chromosome, trisomy 8, isochromosome 17q, or trisomy 19) 
reduces disease-free and overall survival at 5 years by 40%(26)(B).
Recommendation: The presence of additional 
chromosomal aberrations at diagnosis (major route 
abnormalities) reduces the overall and disease-free 
survival and increases mortality by 36% to 40%.
Are the criteria of the World Health Organization 
comparable to other criteria to classify CML phases 
(chronic, accelerated and blast crisis phases)?
The use of the World Health Organization (WHO) 
classification of CML stratifies patients into chronic, accelerated 
and blast crisis phases at approximate rates of 77.8%, 15.5% and 
6.7%, respectively(27)(C). The appropriate classification allows 
the establishment of adequate estimates of response(28)(D).
In the treatment of CML patients with imatinib, there is no 
difference in the overall classification of patients in the chronic, 
accelerated and blast crisis phases between the standard method 
and the WHO criteria. The distribution of patients according to the 
standard classification is about 60% in the chronic phase, 28% in 
the accelerated phase and 12% as blast crisis. Although there is 
no significant difference between the two classifications, 6% of 
patients classified in the chronic phase by the standard classification 
were reclassified in the accelerated phase (WHO). Similarly, 9% of 
patients classified in the accelerated phase were reclassified as blast 
crisis (WHO), and 7% in the chronic phase(29)(B).
There are differences between the M. D. Anderson Cancer 
Center (MDACC), International Bone Marrow Transplant 
Registry (IBMTR) and WHO classifications and definitions 
of the accelerated phase of CML particularly in respect to the 
percentages of blasts and platelets (Table 1)(30)(D):
Table 1 - A comparison between the M. D. Anderson Cancer Center, 
International Bone Marrow Transplant Registry and World Health 
Organization classifications and definitions of the accelerated phase of CML
Characteristic MDACC IBMTR WHO
Blasts (%) > 15 > 10 10 – 19
Platelets < 100 No response < 100 or > 1000
MDACC: M. D. Anderson Cancer Center; IBMTR: International Bone Marrow 
Transplant Registry; WHO: World Health Organization (main differences)
Recommendation: The WHO classification for the 
chronic, accelerated and blast crisis phases of CML are 
similar to the IBMTR and MDACC classifications.
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Is imatinib better than second-generation tyrosine 
kinase inhibitors as first-line treatment of chronic 
phase CML?
A comparison between dasatinib (100 mg) and imatinib 
(400 mg) as first-line treatment in chronic phase CML patients 
demonstrates that complete hematologic response is 11% higher, 
cytogenetic response is 11% higher and molecular response is 
18% higher with dasatinib (NNT: 9)(41)(B). The two-year follow-
up of these patients upholds the higher beneficial effect of 
dasatinib compared to imatinib(42)(B).
Initial treatment of chronic phase CML patients using 
nilotinib (300 mg or 400 mg twice daily) compared to imatinib 
(400 mg once daily) increases the molecular response at 12 
months by 22% (NNT: 5), increases the cytogenetic response by 
15% (NNT: 7) and reduces the likelihood of progression to the 
accelerated and blast crisis phases(43)(A). In the two-year follow 
up, the effect of nilotinib increases the molecular response to 27% 
(NNT: 4), the cytogenetic response is 10% higher than imatinib 
(NNT: 10) with this difference being 5% lower than the evaluation 
at 12 months. The reduction in progression to the accelerated and 
blast crisis phases is maintained(44)(A).
Recommendation: Dasatinib and nilotinib provide 
greater benefits than imatinib in the first-line treatment of 
chronic phase CML patients in respect to the molecular, 
cytogenetic and hematologic responses as well as to the 
progression of the disease.
Does the time between diagnosis and start of treatment 
with imatinib have prognostic importance?
In chronic phase CML patients, imatinib treatment may be 
started after diagnosis (early), or may be started after 24 months 
of treatment with interferon (late), leading to different results 
regarding toxicity and effectiveness. Early treatment reduces the 
risk of grade I and II adverse effects by 52% (NNT: 2) and grade III 
and IV adverse effects by 81% (NNT: 1), although it increases the 
risk of neutropenia and thrombocytopenia by 5% (NNH: 20). After 
one year of follow-up in patients who have not achieved complete 
cytogenetic response, early treatment produces a reduction in the 
risk of grade I adverse events by 3% (NNT: 33), grade II by 8% 
(NNT: 12) and grades III and IV by 7% (NNT: 14)(45)(B).
In early treatment, there is a 16% increase in complete 
cytogenetic response (NNT: 7), a 2% reduction in the risk of 
relapse (NNT: 50) and a 15% increase in disease-free survival 
(NNT: 7)(45)(B).
There is reduction in the risk of non-hematological 
adverse events with early treatment, including weight gain 
(11%), periorbital edema (12%), rash (9%), diarrhea (11%), and 
infections (19%), but there is increased risk of hemorrhage (5%) 
and bone pain (8%)(45)(B).
Imatinib treatment at diagnosis of chronic phase CML 
(early treatment) increases the likelihood of major molecular 
response by 20% (NNT: 5) and increases the likelihood of 
response maintenance at 30 months by 36% (NNT: 3) compared 
to beginning treatment one year after diagnosis (late treatment). 
After one year of imatinib treatment, the likelihood of loss of 
or not achieving molecular response is 58% lower than patients 
treated early (NNT: 2)(46)(B).
Treatment with 400 mg imatinib produced higher major and 
complete cytogenetic response rates compared to the interferon and 
cytarabine combination in chronic phase CML patients (87.1% vs. 
34.7%) and higher progression-free survival to the accelerated and 
blast crisis phases (96.7% vs. 91.5%; p-value < 0.001)(32)(A).
Recommendation: Imatinib treatment of chronic phase 
CML patients should be started as early as possible after 
diagnosis.
Does the cytogenetic evaluation have an impact on 
prognosis?
The identification of CML patients on imatinib treatment with 
cytogenetic clonal evolution provides some information on the 
prognosis that depends on the disease phase. The presence of this 
change in the chronic and accelerated phases is not associated to a 
different cytogenetic response, however it reduces the survival rate 
of patients. Cytogenetic response after three months of treatment 
is an independent prognostic factor. The absence of complete or 
partial response is associated with lower survival rates(47)(B).
In CML patients on imatinib treatment, the presence of a 
cytogenetic response increases 4-year survival by 23% (NNT: 4) 
and disease-free survival by 38% (NNT: 3)(48)(B).
The rate of cytogenetic response in patients in late chronic 
phase CML after interferon alpha intolerance or resistance 
was 55%. After 6 years of treatment with imatinib, 77% of the 
patients were still with stable complete cytogenetic response, 
with a survival rate of 91%. Among the 124 patients who never 
achieved a complete cytogenetic response, 54 (44%) progressed 
to the accelerated or blast crisis phases(49)(B).
The expected loss of cytogenetic response in the first year 
of imatinib treatment is 0.6%, with the mortality rate at 2 years 
of patients who achieved response being lower. The estimated 
8-year mortality rate of these patients is 4.8%(50)(B).
For CML patients unresponsive to imatinib and thus 
treated with second-generation TKIs (dasatinib and nilotinib), a 
cytogenetic response confers 20% greater survival (NNT: 5), and 
when associated with hematological response, the increase in the 
survival rate is 42% (NNT: 2)(51)(B).
The presence of minor or major cytogenetic response 
in chronic phase CML patients under treatment with second-
generation TKIs, increases event-free survival, overall survival 
and disease-free survival by about 25% (NNT: 4)(52)(B).
Recommendation: the cytogenetic evaluation of patients 
under TKI treatment can predict the prognosis by complete 
or partial response, associated or not to other factors.
371
Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project – 2012
Rev Bras Hematol Hemoter. 2012;34(5):367-82
Does molecular evaluation by quantitative real 
time polymerase chain reaction have an impact on 
prognosis?
The BCR-ABL/ABL ratio is almost always below 2% in 
chronic phase CML patients who attain cytogenetic response on 
imatinib treatment. Patients with the BCR-ABL/ABL ratio below 
0.0001% are regarded as having complete molecular response. 
For patients who lose the cytogenetic response within 24 months 
(2.5%) the mean value of the ratio is 0.12%. Some relapsed 
patients evolve with disease progression (15.4%) with BCR-
ABL/ABL ratios that vary from 0.3% to 0.0075%, which, within 
the usefulness of quantitative real time PCR (qPCR) in molecular 
evaluation defines the extremes of positive or negative residual 
disease, but with a great variability in the mean(53)(B).
In CML patients investigated using qPCR, the estimated 
5-year major molecular response rate is 67.1% and the 
cytogenetic response is 81.7%. In respect to event-free survival, 
including transformation to accelerated and blast crisis phases, 
death from any cause, loss of adherence to treatment or loss of 
cytogenetic response, patients who attain molecular response 
have a higher response compared to those who do not. Patients 
with major molecular response have better survival than patients 
with complete cytogenetic response, who do not achieve major 
molecular response(54)(B).
The estimated molecular response obtained by PCR analysis 
in CML patients treated with imatinib, also allows a comparison 
with hematologic and cytogenetic responses over time. Thus, in an 
18-month follow-up, the molecular, cytogenetic and hematologic 
responses were 79%, 83% and 93%, respectively(55)(B).
Cytogenetic progression (loss of response, clonal evolution, 
20% increase of the Philadelphia clone) occurs in 13% of CML 
patients under imatinib treatment in 2 years of follow-up. At the 
time of progression, none of these patients had major molecular 
response (reduction ≥ 3log in BCR-ABL). Thus, there is a 
suggestion that cytogenetic analysis should be restricted to cases 
that do not attain or lose molecular response as measured by 
qPCR(56)(B).
To evaluate changes in the levels of BCR-ABL transcripts 
as prognostic markers by qPCR, monitoring during 4 years 
demonstrates major molecular response (≥ 3-log reduction) and 
predicts higher disease-free survival rates. A minimal increase of 
0.5-log predicts shorter relapse-free survival. Loss of molecular 
response (< 2.5-log reduction) also defines reduction in disease-
free survival. A complete molecular response (PCR undetectable) 
corresponds to an increased disease-free survival(57)(B).
Recommendation: the prognosis (survival, relapse, 
progression) of CML patients under imatinib treatment 
can be predicted using qPCR.
Can cytogenetics be replaced by quantitative real-time 
polymerase chain reaction to monitor CML patients 
taking tyrosine kinase inhibitors who attain complete 
cytogenetic response?
There is a correlation between the levels of transcripts in the 
bone marrow and peripheral blood at 3 months of treatment and 
obtaining molecular response at 6 months(58)(B).
The comparison between qPCR, cytogenetics and 
fluorescence in situ hybridization (FISH) to monitor response to 
treatment using TKIs in CML patients demonstrates the following 
correlations and/or concordances: qPCR in bone marrow and 
peripheral blood; cytogenetics in the bone marrow, FISH in 
peripheral blood and qPCR in peripheral blood(59)(B).
Despite the correlation between qPCR and cytogenetic 
analysis, other prognostic factors may be associated with 
molecular or cytogenetic responses, affecting the outcomes 
during TKI treatment of chronic phase CML patients. This shows 
the need of multivariate analyses that estimate the impact of the 
interaction of prognostic factors present in the medical practice. 
However in multivariate analysis, just the 3-month cytogenetic 
response is predictive of the response at 6 months and disease-
free survival at 2 years(58)(B).
Relapse occurs at 24 months in 2.5% of patients who have 
obtained cytogenetic response and these patients may experience 
disease progression to the accelerated and blast crisis phases. The 
correlation between PCR analysis and cytogenetic response may 
contain a raneg of values that hamper interpretation and thus not 
favor the substitution of methods(53)(B).
Three-monthly monitoring using qPCR may provide the 
prognostic data needed for decision making in CML patients 
thereby reducing the need of bone marrow aspirations. The 
reasons that PCR monitoring is sufficient include: the level of log 
reduction in the BCR-ABL/ABL ratio correlates with cytogenetic 
response; in the 12 -month follow-up, no patient has disease 
progression without there being an indication in the risk by 
qPCR (half-log increase or 5-fold increase in the previous value 
of the BCR-ABL/ABL ratio); and no patient has cytogenetic 
progression when they have molecular response(56)(B).
Recommendation: qPCR in peripheral blood can be used 
as the examination of choice to monitor chronic-phase 
CML patients under imatinib treatment. Cytogenetics is 
a fundamental option for monitoring that may be used in 
association with PCR, or may be reserved for cases where 
either there is no molecular response or the molecular 
response was lost.
What is the treatment of choice for chronic-phase 
CML patients resistant to imatinib 400 mg?
A comparison of treatment with dasatinib 140 mg and 
an increase in the dose of imatinib (800 mg) in chronic phase 
CML patients resistant to imatinib 400 mg (lack of complete 
hematological response at 3 months or lack of cytogenetic 
response at 6 months, or lack of major cytogenetic response at 12 
months of treatment) demonstrates the following results: complete 
hematologic response increases in 11% of patients (NNT: 9), 
complete cytogenetic response increases by 23% (NNT: 4) and 
major molecular response increases by 12% (NNT: 8). Moreover, 
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there are 27% and 15% reductions in the risk of swelling and 
water retention, respectively with dasatinib 140 mg. However, 
the risk of neutropenia and thrombocytopenia increases by 22% 
(NNH: 5) and 42% (NNH: 2), respectively(60)(B). These results 
remain constant at 18 months of follow-up with an increase in 
disease-free survival(61)(B).
The treatment of these patients (CML in chronic phase, 
resistant to imatinib) with dasatinib 100 mg/day compared to 140 
mg/day leads to a similar clinical response in 6 months and 2 
years of follow-up (complete hematologic response, cytogenetic 
response and disease-free survival), however the risk of pleural 
effusion is reduced by 9% (NNT: 11), of thrombocytopenia by 
15% (NNT: 7) and of discontinuity of treatment(62,63)(A).
The response rate of chronic phase CML patients under 
nilotinib treatment (400 mg b.i.d) is no different to patients 
resistant or intolerant to imatinib (600 mg/day). The lack of 
response to imatinib (hematologic or cytogenetic) predicts 
absence of response to nilotinib(64)(B). Patients who attain a 
response with nilotinib remain with 96% to 98% of the response 
(hematologic or cytogenetic) at 6 months of follow-up(65)(B). 
The mean time to obtain a complete hematologic response is 
2.8 months and complete cytogenetic response is 3.2 months, 
with disease-free survival and overall survival at 24 months 
being estimated at 64% and 87%, respectively(66)(B). Patients 
resistant to imatinib or dasatinib treatment attain 79% complete 
hematologic response and 24% complete cytogenetic response 
at 12 months(67)(C).
In chronic phase CML patients resistant to imatinib and 
dasatinib, treatment with bosutinib (500 mg/day) produces 
complete hematological and complete cytogenetic responses 
in 62% and 31% of the cases, respectively. Patients resistant to 
imatinib and nilotinib treatment achieve complete hematological 
and complete cytogenetic responses in 75% and 35% of cases 
taking bosutinib (500 mg/day). In cases of resistance to imatinib 
or dasatinib, the likelihood of maintaining response, disease-free 
survival and overall survival from 12 months on are 27%, 32.4% 
and 72.9%, respectively. In patients resistant to imatinib and 
nilotinib treated with bosutinib, the odds of maintaining response, 
disease-free survival and overall survival from 12 months, are 
22.2%, 44.4% and 77.7%, respectively(68)(B).
Recommendation: Chronic phase CML patients, who are 
resistant to imatinib at a dose of 400 mg, should be treated 
with dasatinib (100 mg/day), nilotinib (800 mg/day) or 
bosutinib (500 mg/day).
Are there differences in the toxicity profiles of second-
generation tyrosine kinase inhibitors (dasatinib and 
nilotinib)?
The difference in adverse effects between imatinib with 
nilotinib or dasatinib is expressed as the NNT; when these latter 
two drugs produce a reduction in the risk of adverse effects and 
the number needed to harm (NNH) when the risk of a particular 
adverse effect increases.
The use of nilotinib (at any dose) as first-line therapy of 
patients with newly diagnosed CML reduces the rates of nausea 
(NNT: 8), diarrhea (NNT: 7), vomiting (NNT: 6), muscle spasm 
(NNT: 6), edema (NNT: 11) and neutropenia (NNT: 3) when 
compared to imatinib. However, the rates of rash (NNH: 4), 
headache (NNH: 8), pruritus (NNH: 8) and alopecia (NNH: 11) 
are increased and there are increases in liver enzymes (NNH: 2), 
total bilirubin (NNH: 2) and glucose (NNH: 5)(43)(A).
When nilotinib is given as second-line therapy in chronic 
phase CML patients, cardiotoxicity can occur with increases in 
the QT interval (QTc - 1% of cases) and thrombocytopenia (29% 
of cases)(65)(B).
In a comparison of dasatinib and imatinib as first-line therapy 
for CML, the main non-hematological adverse effects including 
nausea (NNT: 9), myositis (NNT: 8) and water retention (NNT: 
4) are reduced with dasatinib. However, there are increases in 
pleural effusion in 10% (NNH: 10), thrombocytopenia in 9% 
(NNH: 11) and cardiotoxicity in 0.4%(41)(B).
As second-line therapy in chronic-phase CML patients, 
dasatinib produces increases in the rates of pleural effusion 
(NNH: 6), neutropenia (NNH: 5), thrombocytopenia (NNH: 2), 
dyspnea (NNH: 6) and headache (NNH: 7)(60)(B).
Recommendation: With regards to most expected adverse 
effects using this class of medication, dasatinib and 
nilotinib have similar results but with slight differences 
in the degree. However, nilotinib seems to cause more 
hepatotoxicity and dasatinib causes more water retention 
(pleural effusion).
Does adherence to imatinib treatment have prognostic 
impact?
CML patients on imatinib treatment who have suboptimal 
response are less adherent to treatment (do not take the 
medication) than patients  with optimal response. Patients treated 
for more than 12 months who have complete cytogenetic response 
also have better compliance than those with partial cytogenetic 
response. There is no difference in the hematologic response 
between adherent and non-adherent patients(69)(B).
There is a direct correlation between adherence (≤ 90% or 
> 90%) of CML patients to imatinib treatment and the likelihood 
of major molecular response at 6 years (an increase in 66.1% of 
response in adherence > 90%). When adherence is less than 80% 
there is no molecular response. Patients who need to increase the 
dose of imatinib have 12.8% reduction in adherence(70)(B).
In the treatment of CML with imatinib, ≤ 85% adherence 
increases the risk of loss of complete cytogenetic response 
by 34.9% (NNH: 3). No patients with adherence ≥ 95% lose 
cytogenetic response. Patients with adherence level ≤ 85% who 
never attained molecular response, have low adherence as a 
predictor of loss of cytogenetic response. Adherence of ≤ 85% 
reduces the disease-free survival by 37% (NNH: 3). Adherence 
rates of more than 85% confer a similar prognosis as patients who 
have major molecular response(71)(B).
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The 5-year disease-free survival in chronic phase CML 
patients who adhere to imatinib treatment is 16.9% higher than for 
non-adherent patients. Non-compliance reduces the possibility of 
complete cytogenetic response by 18% (NNH: 6). The greatest 
cause of cessation of imatinib treatment (29.6%) is related to 
noncompliance. Complete cytogenetic response is correlated 
to adherence to treatment, with a reduction in the response in 
noncompliant patients by 20%(72)(B).
Recommendation: adherence to imatinib treatment is 
directly correlated to the probability of molecular and 
cytogenetic responses and disease-free survival.
Are prior cytogenetic response to imatinib and 
performance status prognostic factors for response 
to second-line tyrosine kinase inhibitors in imatinib-
resistant patients?
The best cytogenetic response (0% positive Philadelphia 
chromosome) during treatment with imatinib is predictive of 
response to dasatinib and nilotinib, with an increase in cytogenetic 
response by 21% when compared to no cytogenetic response 
during treatment with imatinib, i.e. Philadelphia ≥ 95% (52)(B).
The response to second-line TKI of Imatinib-resistant CML 
patients is associated with some other prognostic factors such as: 1. 
low-risk Sokal: 25.5% increase in cytogenetic response and 27.0% 
in disease-free survival; 2. percentage of positive Philadelphia 
chromosome at the beginning of treatment < 95%: 43.8% increase 
in the cytogenetic response and 27.3% in disease-free survival; 3. 
time to therapeutic failure of imatinib ≤ 6 months: 37.2% increase 
in cytogenetic response, 24.3% increase in overall survival rate and 
13.8% increase in progression-free survival(52)(B).
The prognosis of treatment using second-line TKIs (nilotinib 
or dasatinib) in Imatinib-resistant CML patients can be predicted 
by prior cytogenetic response (imatinib), giving an estimated 37% 
increase in disease-free survival at 3 years and in the cytogenetic 
response at 1 year. A performance status (European Cooperative 
Oncology Group - ECOG) of “0” at the beginning of treatment 
with second-line TKIs, predicts an 18% increase in disease-free 
survival and a 32% increase in overall survival at 3 years(73)(B).
Other prognostic factors may be associated with response to 
treatment with nilotinib or dasatinib such as: age greater than 55 
years with a 24% reduction in cytogenetic response at 1 year, a 20% 
reduction in disease-free survival at 3 years and a 6% reduction 
in overall survival at 3 years; ≥ 90% Philadelphia chromosome-
positive metaphases at start of treatment with second-line TKIs 
with a 30% reduction in the cytogenetic response and a 21% 
reduction in disease-free survival(73)(B).
Recommendation: Information related to cytogenetic 
response and performance status (ECOG) should be used 
to assess prognosis on starting second-line treatment with 
TKIs such as nilotinib or dasatinib in Imatinib-resistant 
CML patients. Additionally age and cytogenetic response 
prior to treatment with second-generation TKIs should be 
taken into account.
When is it necessary to make an analysis of BCR-
ABL mutations in CML patients under treatment with 
tyrosine kinase inhibitors?
BCR-ABL mutations are associated to 100% resistance to 
imatinib treatment in accelerated-phase CML patients and in 79% 
of chronic-phase patients(74)(C). 
The presence of BCR-ABL mutations increases the risk by 
52% of chronic-phase CML patients evolving to the accelerated 
or blast crisis phases within 9 months (NNH: 2). These mutations, 
especially P-loop mutations, also reduce the time free of disease 
progression and survival of these patients(75)(B).
In the follow-up of CML, BCR-ABL mutations occur at 
different times in patients under treatment with imatinib and are 
correlated with lower survival rates. For patients in the early phase of 
the disease, mutations are associated with increases in transformation 
to the accelerated (32%) and blast crisis phases (16%) and a reduction 
in the complete cytogenetic response (24%). Regardless of the stage 
of the disease, mutations reduce hematologic response(76)(B).
BCR-ABL mutations in CML patients under imatinib 
treatment predict, within about 20 months, loss of complete 
cytogenetic response and progression to the advanced stages of 
the disease(77)(B).
Hematologic and cytogenetic responses are similar in 
patients with and without BCR-ABL mutations under treatment 
with second-generation TKIs (dasatinib and nilotinib). Moreover 
disease-free survival and overall survival are not significantly 
different between these two groups of patients(78)(B).
In the four-year follow-up of chronic phase CML patients, the 
time from the beginning of imatinib treatment to the progression 
of the disease to the accelerated or blast crisis phases is worse in 
patients with mutations than those without mutations. The overall 
survival of patients without mutations and those with mutations is 
51 and 10 months, respectively but this varies according to the type 
of mutation (P-loop type - 13 months and T315I - 9 months)(79)(B).
Among chronic phase CML patients under nilotinib 
treatment, the two-year overall survival is reduced by 38% in the 
presence of BCR-ABL mutations. In addition, the presence of 
mutations is associated with a 34% reduction in the cytogenetic 
response(80)(B).
T315I mutations occur more often in patients treated with 
dasatinib. The presence of mutations during nilotinib or dasatinib 
treatment is predictive of a worse prognosis in these patients(21)(B).
Recommendation: BCR-ABL mutations should 
be investigated in CML patients resistant to TKIs 
(suboptimal response or failure) regardless of the 
stage, because their presence predicts the greater risk 
of resistance and shorter survival.
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Does the diagnosis of mutations guide the choice of 
treatment in imatinib-resistant patients?
In imatinib-resistant CML patients, mutations can assist in 
the choice of second-generation TKIs (nilotinib or dasatinib). An 
evaluation of the sensitivity of mutations to inhibitors in in vitro 
studies (IC
50
) defines three groups of sensitivity (low, intermediate 
and high concentrations) of the mutation to: dasatinib (IC
50
 ≤ 3 nM, 
3-60 nM and > 60 nM) and nilotinib (IC
50
 ≤ 50 nM, 50-500 
nM and > 500 nM) with the worst case scenario (resistance) 
corresponding to high concentrations(78)(B).
Hematologic and cytogenetic responses at one year are 
significantly lower in patients with mutations and in the chronic 
phase, particularly for mutations with intermediate IC
50
 (25% 
and 25%, respectively) compared to low IC
50
 (96% and 54%, 
respectively). In the accelerated phase there is also a reduction 
in the cytogenetic response for mutations with 10% reduction 
in intermediate IC
50
 and 31% reduction in low IC
50
,(78)(B). In the 
chronic phase, the disease-free survival and overall survival are 
lower in patients with mutations with high IC
50
 (0% and 75%, 
respectively), when compared with mutations with low IC
50
 (78% 
and 100%, respectively)(78)(B). The T315I mutation is associated 
with high IC
50
 (resistance) but there is no difference comparing 
dasatinib and nilotinib(78)(B).
Other specific mutations associated with high IC
50
 
(resistance) in the chronic phase of CML treated with dasatinib 
are: T315I/A, F317L/I/V/C and V299L(81-83)(B), and with 
nilotinib: T315I, Y253H, E255K/V and F359V/C(82,84)(B). The 
G250E mutation also has an impact on resistance common in the 
two forms of treatment(83)(B).
Mutations associated with resistance to dasatinib such as 
V299L, T315A and F317I may be sensitive to nilotinib, while the 
mutation V299L may be resistant to bosutinib(83-85)(B).
Complete cytogenetic response subsequent to treatment 
using dasatinib or nilotinib is lower in patients with resistant 
mutations [mutations detected by sequencing that confer 
resistance to the inhibitor received (0%) - T315I, F359V/C, 
F317L, Y253H, E255V/K] compared to patients with other 
mutations (mutations detected by sequencing or spectrometry of 
masses sensitive to the inhibitor received) or without mutations 
(41% and 49%, respectively). The survival of chronic phase CML 
patients when resistant mutations are detected is 0% compared 
with 51% and 45% in patients with other mutations or without 
mutations, respectively(86)(B).
Recommendation: the identification of mutations, 
especially resistant mutations, can assist in the choice 
of the TKI, allowing the definition of which therapeutic 
option will provide the best response.
How should monitoring of CML patients taking 
tyrosine kinase inhibitors be performed?
Reports state that monitoring of chronic-phase CML 
patients for BCR-ABL mutations during imatinib treatment can 
be achieved with PCR in peripheral blood (BCR-ABL/ABL 
ratio) correlating this with the result obtained through the usual 
cytogenetic study of bone marrow. This identifies responsive, 
partial responsive and unresponsive patients in respect to BCR-
ABL/gene control of up to 0.08%, of 0.08% to 10% and of 
above 10%, respectively(87)(B).
In a randomized trial, 1106 CML patients were treated 
with interferon or imatinib as first-line treatment. All patients 
who achieved cytogenetic remission performed qPCR for 
BCR-ABL mutations. The results were expressed in terms 
of the logarithmic reduction in relation to the median level 
of transcripts in 30 newly-diagnosed patients. Patients who 
achieved complete cytogenetic remission and at least a 3-log 
reduction in the level of transcripts, had progression-free 
survival of 100% at 24 months compared to 95% for those with 
complete cytogenetic remission and less than a 3-log reduction 
in the level of transcripts and 85% for patients without complete 
cytogenetic response(88)(B).
Thus, this form of monitoring also allows you to identify 
the 2-year progression-free survival with the low values of 
transcripts(58,88)(B).
Using samples from 38 international centers, one study 
validated the use of an international scale of BCR-ABL values 
that established 0.1% as a 3-log reduction(89)(B).
It is possible to stratify patients by PCR during the 3 years 
follow-up as patients whose indexes reflect increases, stability or 
reduction, or even loss of cytogenetic response(53)(B).
Plasma imatinib levels are significantly higher in patients 
with molecular and cytogenetic responses compared to patients 
without response. The level that differentiates the difference 
between molecular response and lack of response with the 
greatest accuracy (77% sensitivity and 71% specificity) is 1002 
ng/mL(90)(B).
The use of FISH to monitor CML patients on imatinib 
treatment enables the use of peripheral blood to identify 
cytogenetic response. A positive result points to the absence 
of cytogenetic response and a negative result identifies its 
presence. The association with PCR allows the molecular 
response to be monitored. In a study published by Reinhold 
et al., the estimated cytogenetic and molecular responses at 5 
years were 81.7% and 67.1%, respectively(54)(B). However, the 
comparison between the results of FISH using peripheral blood 
leukocytes and the cytogenetics of the bone marrow may not 
establish an appropriate correlation in the measurement of CML 
activity during imatinib treatment(91)(B).
The existence or occurrence of mutations in CML 
patients under TKI treatment, when identified, enables an 
estimation of the prognosis and guides treatment. High-
performance liquid chromatography (HPLC) is a practical 
and sensitive method to identify mutations to clinically 
monitor patients(92)(B).
Some mutations can be identified by direct sequencing 
during the follow-up of patients including: T315T, T315I, F317L, 
V339L, M351T, E355G, Y253F and F359V; these are associated 
with different responses to available inhibitors. A 31% reduction 
in the overall survival of patients with mutations is identified in 
the 3-year follow-up(74)(B).
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Recommendation: The monitoring of CML patients 
treated with TKIs can be accomplished by bone marrow 
cytogenetics and qPCR for the BCR-ABL gene in 
peripheral blood, thereby allowing an estimation of 
prognosis and the definition of therapeutic strategies. 
Mutational analysis should be performed in patients with 
suboptimal response or loss of response to TKIs.
When should bone marrow transplantation be 
indicated for CML patients?
Imatinib may be used as treatment for relapse after allogeneic 
hematopoietic stem cell transplantation, the prevalence of which 
ranges from 40% to 70% at 5 months. In the chronic phase, 
the cytogenetic and hematologic response rates obtained and 
survival at 9 months are 58%, 84% and 100%, respectively(93,94)
(B). Imatinib came to be used as first-line treatment in the chronic 
phase of CML demonstrating increased survival when used 
before bone marrow transplant(95)(B).
Due to the lower cost, resistance to imatinib or advanced stages 
of the disease (accelerated and blast crisis phases), some series of 
cases of transplant in CML have been reported with comparative 
results or in association to imatinib, demonstrating similar disease-
free survival, overall survival and cardiotoxicity(96)(C).
The previous use (before transplantation) of imatinib in 
patients with advanced stages of CML, produces hematological 
response in 73% and cytogenetic response in 40% of patients, 
and 3 years after the transplant, 66.7% of patients have complete 
molecular response(97)(C).
In a prospective study, Jiang et al. compared accelerated 
phase patients treated either with imatinib (n = 87) or allogeneic 
transplantations (n = 54). In this study, multivariate analysis 
established hemoglobin < 10.0 g/dL, blasts in peripheral blood ≤ 
5% and disease duration of less than 12 months as independent 
risk factors for survival. High-risk (two risk factors or more) 
or intermediate-risk patients (one risk factor) had better overall 
survival and progression-free survival with allogeneic transplant. 
No difference was seen with low-risk patients(98)(BII).
The mortality of CML patients on imatinib treatment 
associated to hematopoietic stem cell transplant is 9.7% and the 
relapse rate is 5.0% at one year(99)(C).
Despite the new options in imatinib-resistant patients, 
such as dasatinib and nilotinib, non-comparative case series that 
associate TKIs and transplant are still being performed(100)(C).
Data are still limited for the pediatric population, but the 
results with imatinib are similar to those seen in adults. Millot 
et al. published their experience in 44 children with newly 
diagnosed CML treated with imatinib. With a median follow-
up of 31 months, the estimated progression-free survival at 36 
months was 98%. The rates of complete cytogenetic response 
and major molecular response at 12 months were 61% and 31%, 
respectively. About 30% of the children discontinued the use of 
medication, mainly due to lack of effectiveness. There are adverse 
effects of TKIs on the growth of children and this aspect should 
be monitored(101)(BII).
Moreover, researchers reported the results of a prospective 
study involving 200 CML children and adolescents treated by 
allogeneic transplantation according to donor availability. The 
probability of survival at five years was 87 ± 11% for matched 
related donors, 52 ± 9% for matched unrelated donors and 45 ± 
16% for unmatched donors. The likelihood of relapse at 5 years 
was 20 ± 12%(102)(BII).
Recommendation: Bone marrow transplantation is a 
therapeutic option to treat CML but it should be reserved for 
cases resistant to TKI treatment and patients in the advanced 
stages of the disease after an initial course of TKIs.
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Appendix 1
Search strategies and words used in to answer the clinical 
questions:
PICO 1
What are the diagnostic criteria for chronic myeloid leukemia?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR 
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR 
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, 
Chronic OR Chronic Myelocytic Leukemia OR Leukemia, 
Myelogenous, Chronic OR Myelogenous Leukemia, 
Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive OR 
Myelogenous Leukemia, Chronic OR Myeloid Leukemia, 
Philadelphia-Positive OR Granulocytic Leukemia, Chronic 
OR Leukemia, Myeloid, Chronic, Atypical, BCR-ABL 
Negative) AND (classification OR criteria OR World Health 
Organization* OR standards*) AND (sensitiv*[Title/
Abstract] OR sensitivity and specificity[MeSH Terms] OR 
diagnos*[Title/Abstract] OR diagnosis[MeSH:noexp] OR 
diagnostic * [MeSH:noexp] OR diagnosis,differential[MeSH
:noexp] OR diagnosis[Subheading:noexp])
PICO 2
Is there any difference in the prognosis of CML patients 
with p210, e13a2(b2a2) and e14a2(b3a2) or (e1a2)p190 
rearrangements?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR 
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR 
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic 
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, 
Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, 
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic 
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic 
Leukemia, Chronic) AND ((Fusion Proteins, bcr-abl AND 
genetics*) OR p210 OR e13a2 OR b2a2 OR e14a2 OR 
b3a2 OR p190 OR e1a2 OR Isoform*) AND (prognos*[Title/
Abstract] OR (first[Title/Abstract] AND episode[Title/Abstract]) 
OR cohort[Title/Abstract])
PICO 3
At diagnosis, do the Philadelphia chromosome and the 9q 
deletion have prognostic significance?
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((((Leukemia, Myelogenous, Chronic, BCR-ABL Positive 
OR Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR 
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic 
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, 
Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, 
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic 
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic 
Leukemia, Chronic)) AND (Fusion Proteins, bcr-abl OR BCR-
ABL OR BCR/ABL OR 9q OR Philadelphia OR chromosome 
9))) AND (prognos*[Title/Abstract] OR (first[Title/Abstract] 
AND episode[Title/Abstract]) OR cohort[Title/Abstract])
PICO 4
Do cytogenetic abnormalities in addition to the Philadelphia 
chromosome (Ph) at diagnosis have prognostic significance?
((Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR 
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR 
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic 
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, 
Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, 
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic 
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic 
Leukemia, Chronic) AND (Fusion Proteins, bcr-abl OR BCR-ABL 
OR BCR/ABL OR 9q OR Philadelphia OR chromosome 9 OR 
cytogenetic OR additional chromosome abnormalities OR ACAs)) 
AND (prognos*[Title/Abstract] OR (first[Title/Abstract] AND 
episode[Title/Abstract]) OR cohort[Title/Abstract])
PICO 5
Are the criteria of the World Health Organization (WHO) 
comparable to other criteria to classify the CML phases 
(chronic, accelerated and blast crisis phases)?
((Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR 
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR Chronic 
Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic 
Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR 
Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid, 
Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid 
Leukemia, Philadelphia-Positive OR Granulocytic Leukemia, 
Chronic) AND (classification OR staging OR criteria) AND (World 
Health Organization OR WHO) AND ((sensitiv*[Title/Abstract] 
OR sensitivity and specificity[MeSH Terms] OR diagnos*[Title/
Abstract] OR diagnosis[MeSH:noexp] OR diagnostic 
*[MeSH:noexp] OR diagnosis, differential[MeSH:noexp] OR 
diagnosis[Subheading:noexp])) OR (prognos*[Title/Abstract] OR 
(first[Title/Abstract] AND episode[Title/Abstract]) OR cohort[Title/
Abstract]) OR Investigative Techniques OR Comparative study)
PICO 6
Is it important to define risk to CML patients using the Sokal 
and Hasford scores?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR 
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR Chronic 
Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic 
Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR 
Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid, 
Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid 
Leukemia, Philadelphia-Positive OR Granulocytic Leukemia, 
Chronic) AND (Sokal OR Hasford) AND ((sensitiv*[Title/Abstract] 
OR sensitivity and specificity[MeSH Terms] OR diagnos*[Title/
Abstract] OR diagnosis[MeSH:noexp] OR diagnostic 
*[MeSH:noexp] OR diagnosis, differential[MeSH:noexp] OR 
diagnosis[Subheading:noexp]) OR (prognos*[Title/Abstract] 
OR (first[Title/Abstract] AND episode[Title/Abstract]) OR 
cohort[Title/Abstract])) OR (evaluation study OR comparative 
study OR epidemiologic methods))
PICO 7
Is imatinib better than second generation tyrosine kinase 
inhibitors as first-line treatment of chronic phase CML?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR 
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR 
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic 
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, 
Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, 
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic 
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic 
Leukemia, Chronic) AND (nilotinib OR dasatinib) AND imatinib 
AND ((clinical[Title/Abstract] AND trial[Title/Abstract]) OR 
clinical trials[MeSH Terms] OR clinical trial[Publication Type] 
OR random*[Title/Abstract] OR random allocation[MeSH 
Terms] OR therapeutic use[MeSH Subheading])
PICO 8
Does the time between diagnosis and start of treatment with 
imatinib have prognostic importance?
(((((((Leukemia, Myelogenous, Chronic, BCR-ABL 
Positive OR Leukemia, Myeloid, Philadelphia-Positive OR 
Leukemia, Granulocytic, Chronic OR Myeloid Leukemia, 
Chronic OR Chronic Myeloid Leukemia OR Leukemia, 
Myelocytic, Chronic OR Chronic Myelocytic Leukemia 
OR Leukemia, Myelogenous, Chronic OR Myelogenous 
Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 
Positive OR Myelogenous Leukemia, Chronic OR Myeloid 
Leukemia, Philadelphia-Positive OR Granulocytic Leukemia, 
Chronic)) AND Imatinib) AND Prognosis/narrow[filter])) 
OR ((((Leukemia, Myelogenous, Chronic, BCR-ABL 
Positive OR Leukemia, Myeloid, Philadelphia-Positive OR 
Leukemia, Granulocytic, Chronic OR Myeloid Leukemia, 
Chronic OR Chronic Myeloid Leukemia OR Leukemia, 
Myelocytic, Chronic OR Chronic Myelocytic Leukemia 
OR Leukemia, Myelogenous, Chronic OR Myelogenous 
Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive 
OR Myelogenous Leukemia, Chronic OR Myeloid Leukemia, 
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Philadelphia-Positive OR Granulocytic Leukemia, Chronic) 
AND Imatinib AND (Time factors OR early OR late OR 
delay*) AND Therapy/broad[filter])) OR ((Leukemia, 
Myelogenous, Chronic, BCR-ABL Positive OR Leukemia, 
Myeloid, Philadelphia-Positive OR Leukemia, Granulocytic, 
Chronic OR Myeloid Leukemia, Chronic OR Chronic Myeloid 
Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic 
Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic 
OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, 
Myeloid, Ph1 Positive OR Myelogenous Leukemia, 
Chronic OR Myeloid Leukemia, Philadelphia-Positive OR 
Granulocytic Leukemia, Chronic) AND Imatinib AND (Time 
factors OR early OR late) AND Prognosis/broad[filter])))) 
OR (((((Leukemia, Myelogenous, Chronic, BCR-ABL 
Positive OR Leukemia, Myeloid, Philadelphia-Positive OR 
Leukemia, Granulocytic, Chronic OR Myeloid Leukemia, 
Chronic OR Chronic Myeloid Leukemia OR Leukemia, 
Myelocytic, Chronic OR Chronic Myelocytic Leukemia 
OR Leukemia, Myelogenous, Chronic OR Myelogenous 
Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive 
OR Myelogenous Leukemia, Chronic OR Myeloid Leukemia, 
Philadelphia-Positive OR Granulocytic Leukemia, Chronic)) 
AND Imatinib)) AND therapy/narrow[filter])
PICO 9
Does the cytogenetic evaluation have an impact on prognosis?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR 
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR 
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic 
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, 
Chronic OR Myelogenous Leukemia, Ph1-Positive OR 
Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia, 
Chronic OR Myeloid Leukemia, Philadelphia-Positive OR 
Granulocytic Leukemia, Chronic) AND (Cytogenetic Analysis 
OR Cytogenetic*) AND ((sensitiv*[Title/Abstract] OR 
sensitivity and specificity[MeSH Terms] OR diagnos*[Title/
Abstract] OR diagnosis[MeSH:noexp] OR diagnostic 
*[MeSH:noexp] OR diagnosis, differential[MeSH:noexp] OR 
diagnosis[Subheading:noexp]) OR (prognos*[Title/Abstract] 
OR (first[Title/Abstract] AND episode[Title/Abstract]) OR 
cohort[Title/Abstract])) OR (evaluation study OR comparative 
study OR epidemiologic methods))
PICO 10
Does molecular evaluation by quantitative real time 
polymerase chain reaction (PCR) have an impact on 
prognosis?
((Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR 
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR 
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic 
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, 
Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, 
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic 
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic 
Leukemia, Chronic) AND (Polymerase Chain Reaction OR 
PCR OR Nested PCR OR Anchored PCR) AND molecular 
AND (prognos*[Title/Abstract] OR (first[Title/Abstract] AND 
episode[Title/Abstract]) OR cohort[Title/Abstract]))
PICO 11
Can cytogenetics be replaced by quantitative PCR (qPCR) to 
monitor CML patients taking tyrosine kinase inhibitors who 
attained complete cytogenetic response?
((Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR 
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR 
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic 
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, 
Chronic OR Myelogenous Leukemia, Ph1-Positive OR 
Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia, 
Chronic OR Myeloid Leukemia, Philadelphia-Positive OR 
Granulocytic Leukemia, Chronic) AND (Cytogenetic Analysis OR 
Cytogenetic*)) AND (Polymerase Chain Reaction OR PCR OR 
Nested PCR OR Anchored PCR OR DNA Mutational Analysis)
PICO 12
What is the treatment of choice for chronic-phase CML 
patients resistant to Imatinib 400 mg?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR 
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR 
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic 
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, 
Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, 
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic 
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic 
Leukemia, Chronic) AND imatinib AND ((clinical[Title/
Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH 
Terms] OR clinical trial[Publication Type] OR random*[Title/
Abstract] OR random allocation[MeSH Terms] OR therapeutic 
use[MeSH Subheading]) AND drug resistance
PICO 13
Are there differences in the toxicity profiles of second-
generation tyrosine kinase inhibitors (dasatinib and nilotinib)? 
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR 
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR 
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic 
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, 
Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, 
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic 
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic 
Leukemia, Chronic) AND (dasatinib) AND (nilotinib) AND 
(adverse effects OR complications OR safety OR toxicity) AND 
(Therapy/broad[filter] OR comparative study OR epidemiologic 
methods OR systematic[sb])
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PICO 14
Does adherence to Imatinib treatment have prognostic 
impact?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR 
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR 
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic 
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, 
Chronic OR Myelogenous Leukemia, Ph1-Positive OR 
Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia, 
Chronic OR Myeloid Leukemia, Philadelphia-Positive OR 
Granulocytic Leukemia, Chronic) AND imatinib AND Prognosis 
AND (Adherence OR Compliance)
PICO 15 
Are prior cytogenetic response with Imatinib and performance 
status prognostic factors for response to second-line tyrosine 
kinase inhibitors in patients resistant to Imatinib?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR 
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR 
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic 
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, 
Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, 
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic 
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic 
Leukemia, Chronic) AND (Cytogenetic Analysis OR Cytogenetic* 
OR performance status OR Karnofsky Performance Status) AND 
Imatinibe AND (Nilotinib OR Dasatinibe) AND ((sensitiv*[Title/
Abstract] OR sensitivity and specificity[MeSH Terms] OR 
diagnos*[Title/Abstract] OR diagnosis[MeSH:noexp] OR diagnostic 
*[MeSH:noexp] OR diagnosis, differential[MeSH:noexp] OR 
diagnosis[Subheading:noexp]) OR (prognos*[Title/Abstract] 
OR (first[Title/Abstract] AND episode[Title/Abstract]) OR 
cohort[Title/Abstract])) OR (evaluation study OR comparative 
study OR epidemiologic methods))
PICO 16
When is it necessary to make an analysis of BCR-ABL 
mutations in CML patients under treatment with tyrosine 
kinase inhibitors?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR 
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR Chronic 
Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic 
Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR 
Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid, 
Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid 
Leukemia, Philadelphia-Positive OR Granulocytic Leukemia, 
Chronic) AND (Fusion Proteins, bcr-abl OR BCR-ABL OR BCR/
ABL) AND (Protein Kinase Inhibitors OR crizotinib OR Cyclin-
Dependent Kinase Inhibitor p15 OR Cyclin-Dependent Kinase 
Inhibitor p18 OR Cyclin-Dependent Kinase Inhibitor p19 OR 
Cyclin-Dependent Kinase Inhibitor p21 OR Cyclin-Dependent 
Kinase Inhibitor p27 OR Cyclin-Dependent Kinase Inhibitor p57 
OR Cyclin-Dependent Kinase Inhibitor Proteins OR dasatinib OR 
erlotinib OR fasudil OR flavopiridol OR gefitinib OR Genistein OR 
imatinib OR lapatinib OR roscovitine OR sorafenib OR vatalanib)
PICO 17
Does the diagnosis of mutations guide the choice of treatment 
in imatinib-resistant patients?
((((Leukemia, Myelogenous, Chronic, BCR-ABL Positive 
OR Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR 
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic 
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, 
Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, 
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic 
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic 
Leukemia, Chronic))) AND (((Fusion Proteins, bcr-abl)) OR 
(Mutation*))) AND (((nilotinib OR dasatinib)) OR (bone marrow 
transplantation))
PICO 18
How should monitoring of CML patients taking tyrosine 
kinase inhibitors be performed? 
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR 
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR 
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic 
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, 
Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, 
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic 
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic 
Leukemia, Chronic) AND (Protein Kinase Inhibitors OR Imatinib 
OR Nilotinib OR Dasatinib) AND (Blood Cell Count OR 
Cytogenetics OR Polymerase Chain Reaction OR Mutation* OR 
In Situ Hybridization, Fluorescence) AND monitor*
PICO 19
When should bone marrow transplantation be indicated for 
CML patients?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR 
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, 
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR 
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic 
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, 
Chronic OR Myelogenous Leukemia, Ph1-Positive OR 
Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia, 
Chronic OR Myeloid Leukemia, Philadelphia-Positive OR 
Granulocytic Leukemia, Chronic) AND BONE MARROW 
TRANSPLANTATION AND (Therapy/broad[filter] OR 
Comparative study)
xxx
